STUDY OF THE NATURAL HISTORY OF CHRONIC NON-A, NON-B HEPATITIS

有充分证据的慢性非甲非乙型肝炎患者 正在进行评估以确定地球的长期自然历史 这种常见的慢性肝病。一群这样的人 患者可以评估这方面的实验疗法。 疾病。在一项初步研究中，10名患者接受了阿尔法- 干扰素。追踪显示，6人似乎有过长期的 肝炎明显完全缓解。在2例中， 反应良好，但暂时的，2名患者无反应 完全没有。一种前瞻性的，随机的，安慰剂对照的，双重- 人α-干扰素6个月疗程的盲法试验 患有慢性NANB肝炎的患者正在进行中。41分 患者已经进入，26人已经完成了6个月的 到目前为止的治疗。接受干扰素治疗的13名患者中有12名显示 血清ALT活性有所下降，其中7例ALT回升 治疗后恢复到正常水平。平均血清ALT活性没有 在任何接受安慰剂治疗的患者中都变得正常。干扰素是 总体来说，容忍程度很好，类似的不利事态发展 在干扰素和安慰剂治疗组中注意到。

Patients with well-documented chronic non-A, non-B (NANB) hepatitis are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies for this disease. In a pilot study, 10 patients were treated with alpha- interferon. Follow up shows that 6 seem to have had a long-term apparently complete remission of the hepatitis. In 2 cases the response was favorable but temporary and 2 patients did not respond at all. A prospective, randomized, placebo-controlled, double- blind trial of a six month course of human alpha interferon in patients with chronic NANB hepatitis is underway. Forty one patients have been entered and 26 have completed 6 months of treatment so far. 12 of 13 patients treated with interferon showed some decrease in serum ALT activity and in 7 of these, ALT returned to normal levels after treatment. Mean serum ALT activity did not become normal in any placebo-treated patients. Interferon was generally well tolerated and similar untoward developments were noted in interferon and placebo treated groups.